Key terms

About VYGR

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest VYGR news

Apr 03 10:52am ET Biotech Alert: Searches spiking for these stocks today Apr 02 4:24pm ET Voyager Therapeutics Announces CFO Transition Plan and Appointment Mar 19 9:53am ET Snowflake, MongoDB downgraded to Sell: Wall Street’s top analyst calls Mar 19 6:17am ET Voyager Therapeutics: A Buy Rating on Breakthrough CNS Gene Therapy Innovations and Strategic Growth Potential Mar 19 6:05am ET Voyager Therapeutics initiated with a Buy at H.C. Wainwright Mar 13 7:19am ET Voyager Therapeutics appoints Toby Ferguson as CMO Mar 06 5:15pm ET Voyager Therapeutics: A Strong Buy on CNS Gene Therapy Advances and Strategic Partnerships Mar 06 5:05pm ET Voyager Therapeutics initiated with a Buy at Citi Mar 05 7:25am ET Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst Mar 01 7:48am ET Oppenheimer Sticks to Their Buy Rating for Voyager Therapeutics (VYGR) Mar 01 4:58am ET Voyager Therapeutics Buy Rating Affirmed Amid Strong Pipeline and Financial Health Mar 01 1:18am ET Voyager Therapeutics’ Promising Outlook in Gene Therapy: A Strong Buy Recommendation Feb 29 8:02am ET Analysts Conflicted on These Healthcare Names: Immunocore Holdings (IMCR), Voyager Therapeutics (VYGR) and Castle Biosciences (CSTL) Feb 28 6:10pm ET Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Warby Parker (WRBY) Feb 26 7:16am ET Voyager Therapeutics reports selection of gene therapy development candidate Feb 20 7:06am ET Voyager Therapeutics reports preclinical activity on tau silencing gene therapy Jan 11 7:55am ET Oppenheimer Keeps Their Buy Rating on Voyager Therapeutics (VYGR) Jan 10 5:43am ET Voyager Therapeutics: A Strong Buy on Technological Superiority and Strategic Financial Health Jan 05 11:01am ET Biotech Alert: Searches spiking for these stocks today Jan 04 10:59pm ET Voyager Therapeutics 7.778M share Spot Secondary priced at $9.00 Jan 04 8:50pm ET Voyager Therapeutics prices $100M offering at $9 per share, Bloomberg says Jan 04 4:37pm ET Voyager Therapeutics $100M Spot Secondary; price range $9.00-$9.50 Jan 04 4:16pm ET Voyager Therapeutics announces $100M common stock offering

No recent news articles are available for VYGR

No recent press releases are available for VYGR

VYGR Financials

1-year income & revenue

Key terms

VYGR Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VYGR Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms